CN112839962A - 用于治疗癌症的抗mertk抗体 - Google Patents

用于治疗癌症的抗mertk抗体 Download PDF

Info

Publication number
CN112839962A
CN112839962A CN201980067679.7A CN201980067679A CN112839962A CN 112839962 A CN112839962 A CN 112839962A CN 201980067679 A CN201980067679 A CN 201980067679A CN 112839962 A CN112839962 A CN 112839962A
Authority
CN
China
Prior art keywords
seq
amino acids
linked amino
sequence shown
mertk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067679.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·E·小斯皮尔斯
M·奎格利
V·拉方特
G·C·拉凯斯特拉
L·梁
K·A·奥古斯丁-劳赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN112839962A publication Critical patent/CN112839962A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980067679.7A 2018-10-09 2019-10-08 用于治疗癌症的抗mertk抗体 Pending CN112839962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743507P 2018-10-09 2018-10-09
US62/743,507 2018-10-09
PCT/US2019/055155 WO2020076799A1 (en) 2018-10-09 2019-10-08 Anti-mertk antibodies for treating cancer

Publications (1)

Publication Number Publication Date
CN112839962A true CN112839962A (zh) 2021-05-25

Family

ID=68345048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067679.7A Pending CN112839962A (zh) 2018-10-09 2019-10-08 用于治疗癌症的抗mertk抗体

Country Status (6)

Country Link
US (1) US20210395392A1 (cg-RX-API-DMAC7.html)
EP (1) EP3864046A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022512642A (cg-RX-API-DMAC7.html)
KR (1) KR20210072059A (cg-RX-API-DMAC7.html)
CN (1) CN112839962A (cg-RX-API-DMAC7.html)
WO (1) WO2020076799A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591431A (zh) * 2022-05-11 2022-06-07 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN119654342A (zh) * 2022-07-28 2025-03-18 乐普创一生物科技(上海)有限公司 抗MerTK抗体及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002967A (ko) * 2019-04-19 2022-01-07 제넨테크, 인크. 항 mertk 항체 및 이의 사용 방법
PE20221326A1 (es) 2019-12-13 2022-09-09 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos
WO2021202590A1 (en) * 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh) * 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
KR20240082341A (ko) 2021-10-15 2024-06-10 치오메 바이오사이언스 가부시키가이샤 MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591431A (zh) * 2022-05-11 2022-06-07 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN114591431B (zh) * 2022-05-11 2022-08-12 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN119654342A (zh) * 2022-07-28 2025-03-18 乐普创一生物科技(上海)有限公司 抗MerTK抗体及其用途
CN120484126A (zh) * 2022-07-28 2025-08-15 乐普创一生物科技(上海)有限公司 抗MerTK抗体及其用途

Also Published As

Publication number Publication date
KR20210072059A (ko) 2021-06-16
JP2022512642A (ja) 2022-02-07
US20210395392A1 (en) 2021-12-23
EP3864046A1 (en) 2021-08-18
WO2020076799A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
KR102937285B1 (ko) 신규 항-pd-l1 항체
US20210395392A1 (en) Anti-mertk antibodies for treating cancer
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
JP7680208B2 (ja) 抗cd27抗体およびその使用
TW201831511A (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
JP7490923B2 (ja) 免疫療法効果が向上し副作用が軽減した変異抗ctla-4抗体
KR102608723B1 (ko) 항―pd-1 항체 및 그의 용도
KR20200113228A (ko) 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US20220363754A1 (en) Anti-tigit antibodies and application thereof
ES2967381T3 (es) Anticuerpos biespecíficos contra CEACAM5 y CD47
KR20200088810A (ko) 항―ox40 항체 및 그의 용도
CN116199778A (zh) 抗4-1bb抗体及其用途
CN117355331A (zh) 抗Siglec组合物及其用途
JP2024097985A (ja) 抗gitr抗体およびその使用
JP2024507124A (ja) Cd112rに対する抗体およびその使用
JP2025535503A (ja) 抗ccr8抗体及びその使用
JP2025525916A (ja) 抗ccr8抗体及び使用方法
JP2025537137A (ja) 抗ccr8抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
JP2025514847A (ja) Fas軸拮抗薬及びTreg細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
WO2022057910A1 (en) Combination therapies targeting c5ar and pd-1/pd-l1 pathways
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
US20220378909A1 (en) Methods of Treating Cancer with Anti-PD-1 Antibodies
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525